Aridis Pharmaceuticals, Inc. (ARDS)

Market Cap	53.00
Revenue (ttm)	22.36M
Net Income (ttm)	-1.14M
Shares Out	53.32M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,200
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0000 - 0.124
Beta	1.10
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 37
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARDS

Financial Performance

In 2022, Aridis Pharmaceuticals's revenue was $3.09 million, an increase of 101.37% compared to the previous year's $1.54 million. Losses were -$30.37 million, -34.43% less than in 2021.